FDA issues draft guidance to streamline biosimilar approvals, aiming to cut bureaucracy and increase competition for lower-cost biologics.
Caterpillar's record-breaking Q3 driven by strong demand for power generation equipment used in AI data centers, offsetting construction slowdowns and tariff headwinds.
Generac's Q3 earnings miss and reduced 2025 sales and margin guidance send shares tumbling, despite long-term growth drivers remaining intact.
FDA issues draft guidance to streamline biosimilar approvals, aiming to cut bureaucracy and increase competition for lower-cost biologics.
Caterpillar's record-breaking Q3 driven by strong demand for power generation equipment used in AI data centers, offsetting construction slowdowns and tariff headwinds.
Generac's Q3 earnings miss and reduced 2025 sales and margin guidance send shares tumbling, despite long-term growth drivers remaining intact.